3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
11
Recruiting
3
Active not recruiting
2
Withdrawn
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
24
Colorectal Neoplasms
19
Stomach Neoplasms
15
Rectal Neoplasms
13
Triple Negative Breast Neoplasms
10
Neoplasm Metastasis
7
Pancreatic Neoplasms
6
Nasopharyngeal Carcinoma
6
Colonic Neoplasms
6
Neoplasms
4
Gallbladder Neoplasms
4
Cholangiocarcinoma
4
Anus Neoplasms
4
Adenocarcinoma Of Esophagus
4
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Somatostatinoma
2
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Klatskin Tumor
2
Esophageal Squamous Cell Carcinoma
2
Colorectal Cancer Metastatic
2
Clinical Stage I Gastric Cancer AJCC v8
2
Biliary Tract Neoplasms
2
Adenoma, Islet Cell
2
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Solid Cancer
1
Skin Neoplasms
1
Rectal Diseases
1
Interventions
pembrolizumab
35
Cisplatin
12
Paclitaxel
9
lenvatinib
7
Carboplatin
6
belzutifan
5
Saline Solution
4
Pemetrexed
4
Oxaliplatin
4
Fluorouracil
4
Leucovorin
3
Etoposide
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
olaparib
2
enfortumab vedotin
2
durvalumab
2
Surgical Procedures, Operative
2
Radiotherapy
2
Levoleucovorin
2
Glucose
2
Capecitabine
2
Bevacizumab
2
zanidatamab
1
tislelizumab
1
sacituzumab govitecan
1
liposomal doxorubicin
1
enzalutamide
1
balstilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Capecitabine
×
Clear all
NCT05152147
2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3
Active not recruiting
920 enrolled
NCT04895358
2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
340 enrolled